ASX Share rice
Sun 09 Aug 2020 - 06:53:pm (Sydney)

CPH Share Price

CRESO PHARMA LIMITEDCPHPharmaceuticals, Biotechnology & Life Sciences

CPH Company Information

Name:

Creso Pharma Limited

Sector:

Healthcare

Industry:

Drug Manufacturers—Specialty & Generic

Address:

Tower 3 Sydney NSW Australia 2000

Phone:

61 2 8067 8606

Co-Founder & Chairman:

Mr. Boaz Wachtel

Co-Founder, Group CEO & Director:

Dr. Miriam Halperin Wernli

Co-Founder & Non-Exec. Director:

Mr. Adam Blumenthal B.Com., M.B.A.

Chief Financial Officer:

Mr. Chris Grundy

Commercial & Marketing Director:

Dr. Gian Trepp

Company Overview:

Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, and the Asia Pacific. The company is involved in hemp growing operations, outsourced CBD extraction, and cannabidiol (CBD) product sales activities, as well as the development and commercialization of its therapeutic products. Its products include anibidiol, a natural complementary feed product for companion animals; and cannaQIX, a nutraceutical product containing organic hemp extract with CBD vitamins and zinc to reduce stress and support mental and nervous functions in humans, as well as topical and skin care products. The company also offers various nutraceutical products, such as cannaQIX®nite to aid sleep; cannaPEAL to introduce various markets to the benefits of hemp seed oil-based products; and cannaDOL to provide relief to athletes in the form of a topical application. In addition, it imports and sells its medicinal cannabis product, cannaQIX50 to patients in Brazil. Creso Pharma Limited has a strategic collaboration agreement with Hempmate AG Switzerland and Burleigh Heads Cannabis Pty Ltd. The company was incorporated in 2015 and is headquartered in Sydney, Australia.

CPH Share Price Information

Shares Issued:

366.38M

Market Capitalisation:

$11.72M

Revenue (TTM):

$3.63M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.111

Operating Margin (TTM):

$-2.74

Return On Assets (TTM):

$-0.28

Return On Equity (TTM):

$-0.92

Quarterly Revenue Growth (YOY):

6.212

Gross Profit(TTM):

$2.13M

Diluted Earnings Per Share (TTM):

$-0.105

CPH CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$-3,342,231

Change To Liabilities:

$259.59K

Total Cashflow From Investing Activities:

$-3,342,231

Net Borrowings:

$1.30M

Net Income:

$-15,054,381

Total Cash From Operating Activities:

$-10,166,956

Depreciation:

$397.96K

Change To Inventory:

$-1,549,395

Change To Account Receivables:

$-356,877

Sale Purchase Of Stock:

$-291,255

Capital Expenditures:

$3.34M

CPH Income Statement

Income Date:

2019-12-31

Income Before Tax:

$-15,339,772

Net Income:

$-15,054,381

Gross Profit:

$2.13M

Operating Income:

$-10,174,908

Other Operating Expenses:

$247.11K

Interest Expense:

$2.09M

Total Revenue:

$3.63M

Total Operating Expenses:

$12.30M

Cost Of Revenue:

$1.50M

CPH Balance Sheet

Balance Sheet Date:

2019-12-31

Intangible Assets:

$4.48M

Total Liabilities:

$5.39M

Total Stockholder Equity:

$17.65M

Other Current Liabilities:

$179.58K

Total Assets:

$22.66M

Common Stock:

$46.53M

Other Current Assets:

$855.12K

Retained Earnings:

$-51,857,345

Other Liabilities:

$375.04K

Cash:

$2.80M

Total Current Liabilities:

$5.39M

Short-Term Debt:

$3.23M

Property - Plant & Equipment:

$11.27M

Net Tangible Assets:

$12.80M

Total Current Assets:

$6.92M

Net Receivables:

$1.02M

Short-Term Investments:

$15.75M

Inventory:

$2.42M

Accounts Payable:

$1.03M

Non Currrent Assets (Other):

$15.75M

Short-Term Investments:

$15.75

Non Current Liabilities Total:

$0

CPH Share Price History

CPH News

05 Dec, 2019
TORONTO , Dec. 5, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced that Creso Pharma Limited ("Creso") (CPH.AX) has repaid in full, all principal and interest owing to the Company in the amount of approximately CAD$3.9 million under the secured bridge loan by PharmaCielo to Creso that was made pursuant to an amendment to Creso's existing loan deed, originally entered into with an arm's length party to Creso on April 26, 2019 (the "Secured Bridge Loan").